There are hundreds of drug candidates to screen for purity, integrity and stability during early drug development, which can become a considerable bottleneck.

Join us on September 13 to explore the hottest topics and emerging trends in the cannabis testing lab as well as developments within the psychedelics space. Topics of focus will include method development for hemp fibers, auditing to combat cannabis misinformation, streamlining potency processes and identifying heavy metal sources in cannabis and hemp.

This exclusive Ask Me Anything session delves into the cutting-edge advancements and international policy changes driving sustainability in the laboratory.

To adequately assess the safety and efficacy of candidate gene therapies, robust bioanalytical technologies must support regulated studies. Hence, many labs now incorporate the latest qPCR and digital PCR (dPCR) methods into their preclinical and clinical development workflows to assure data accuracy and product effectiveness.

Liquid biopsies and the advent of blood-based diagnostics have emerged in recent years as promising alternatives and complements to tissue-based genomic and proteomic assays. Biodesix, a global leader in molecular diagnostics and assay design/development, leverages cutting-edge technology, including droplet digital PCR (ddPCR), to advance translational and clinical oncology research and to assist biopharma companies in delivering new, targeted, life-saving therapies to patients.

This presentation provides a comprehensive exploration of new blood-based diagnostics, including the development of a microsatellite instability (MSI) test on the ddPCR platform and the dynamic monitoring capabilities of ddPCR using circulating tumor DNA (ctDNA).

This webinar highlights the latest affinity chromatography solutions for the quick and easy purification of multiple AAV serotypes across a variety of column setups.